Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for tough blood cancers

NCT ID NCT05005442

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see if the drug is safe and whether it can shrink tumors. The trial has finished, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-7684A (a combination of two immune-boosting drugs: pembrolizumab and vibostolimab)
What this could lead to
If it works, this could offer a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong
This is an early phase 2 trial, so the drug may not work for many patients. Side effects from immune activation can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

192 people

The number who actually took part.

Started

Sep 2021

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria \- Have confirmed relapsed/refractory classic Hodgkins Lymphoma (cHL), Primary mediastinal B-cell lymphoma (PMBCL), Follicular Lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkins Lymphoma (NHL), or multiple myeloma (MM). For PMBCL, DLBCL, FL, and MM: \- Must be relapsed or refractory to CAR-T-cell therapy or unable to receive it. For DLBCL and NHL: \- Must have exhausted or be ineligible for or intolerant to all treatments, which in the opinion of the investigator are standard of care for their disease. For NHL: \- Participants with Mantle cell lymphoma (MCL) must have received prior Bruton's tyrosine kinase inhibitor therapy. All participants: * Have measurable disease. * Have adequate organ function. * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation. * Must be able to provide newly obtained bone marrow biopsy or aspirate material for disease assessment. * Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of non child-bearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle. Exclusion Criteria For DLBCL and NHL: \- Has lymphoplasmacytic lymphomas, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia (not associated with small lymphocytic lymphoma), Burkitt (-like) lymphoma, mature T cell and NK cell neoplasms, immunodeficiency associated lymphoproliferative neoplasms, or histiocytic and dendritic cell neoplasms. For MM: * Has oligo-secretory myeloma, plasma cell leukemia, smoldering multiple myeloma, or monoclonal gammopathy of undetermined significance. * Has a history of primary amyloidosis, hyperviscosity or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes). * Has known prior or current central nervous system (CNS) involvement. For Epstein Barr virus (EBV) positive DLBCL: \- Associated with a solid organ transplant. For all participants: * A WOCBP who has a positive urine pregnancy test within 72 hours before study intervention allocation. * Has clinically significant cardiovascular disease within 12 months from first dose of study intervention. * Has a history of a second malignancy. * Any PMBCL participants that require the use of urgent cytoreductive therapy. * If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery before starting study intervention. * Has received prior radiotherapy within 2 weeks of start of study intervention. * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. * Has a known severe hypersensitivity to MK-7684A, vibostolimab or pembrolizumab and/or any of its excipients. * Has a known history of Human Immunodeficiency Virus (HIV) infection. * Has an active autoimmune disease that has required systemic treatment in past 2 years. * Has an active infection requiring systemic therapy. * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study. * Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before enrollment. * Has dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and Hepatitis C (HCV) infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry.. * Has had an allogenic hematopoietic stem cell/solid organ transplantation within the last 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classic hodgkins lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm non-Hodgkin lymphoma plasma cell myeloma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancies

Contacts and locations

Locations

  • Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0362)

    Aarhus, Central Jutland, 8200, Denmark

  • Almazov National Medical Research Centre-Intensive care unit No. 10 for oncohematological patients (

    Saint Petersburg, Leningradskaya Oblast', 197341, Russia

  • Ankara University Hospital Cebeci ( Site 0561)

    Ankara, 06100, Turkey (Türkiye)

  • Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 0400)

    Brescia, Lombardy, 25123, Italy

  • BC Cancer Vancouver ( Site 0034)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Chang Gung Medical Foundation-Linkou Branch ( Site 0262)

    Taoyuan, 333, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung ( Site 0263)

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan

  • Cherkasy Regional Oncology Dispensary ( Site 0593)

    Cherkassy, Cherkasy Oblast, 18009, Ukraine

  • City of Hope Comprehensive Cancer Center-Hematology ( Site 0024)

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra ( Site 0444)

    Pamplona, Navarre, 31008, Spain

  • Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0402)

    Debrecen, 4032, Hungary

  • Dokuz Eylül Üniversitesi-Hematology ( Site 0563)

    Izmir, 35340, Turkey (Türkiye)

  • Ege University Medicine of Faculty ( Site 0565)

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • FALP-UIDO ( Site 0623)

    Santiago, Region M. de Santiago, 6900941, Chile

  • Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 0383)

    Rome, Lazio, 00168, Italy

  • GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0548)

    Ufa, Baskortostan, Respublika, 450054, Russia

  • Gustave Roussy-DITEP ( Site 0301)

    Villejuif, Paris, 94800, France

  • Hadassah Medical Center ( Site 0522)

    Jerusalem, 9112001, Israel

  • Henry Ford Hospital ( Site 0003)

    Detroit, Michigan, 48202, United States

  • Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0446)

    Madrid, 28040, Spain

  • Hospital Universitario de Salamanca-Hematology ( Site 0441)

    Salamanca, 37007, Spain

  • Institute of Transfusion Medicine and Blood of the National Academy of Medical Sciences of Ukraine (

    Lviv, Lviv Oblast, 79044, Ukraine

  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 0442)

    L'Hospitalet Del Llobregat, Barcelona, 08908, Spain

  • Instituto Nacional del Cancer ( Site 0626)

    Chile, Region M. de Santiago, 8380455, Chile

  • Instituto do Câncer e Transplante de Curitiba ( Site 0611)

    Curitiba, Paraná, 80510130, Brazil

  • Jewish General Hospital ( Site 0032)

    Montreal, Quebec, H3T 1E2, Canada

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004)

    Hackensack, New Jersey, 07601, United States

  • Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 0325)

    Trier, Rhineland-Palatinate, 54290, Germany

  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0601)

    Natal, Rio Grande do Norte, 59075-740, Brazil

  • MEDICAL COLLEGE OF WISCONSIN ( Site 0016)

    Milwaukee, Wisconsin, 53226, United States

  • McGill University Health Centre ( Site 0037)

    Montreal, Quebec, H4A 3J1, Canada

  • Medical Oncology Associates, PS ( Site 0001)

    Spokane, Washington, 99208, United States

  • Mega Medipol-Hematology ( Site 0567)

    Istanbul, 34214, Turkey (Türkiye)

  • Moscow City Clinical Hospital S.P. Botkin ( Site 0547)

    Moscow, Moscow, 125284, Russia

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0427)

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Institute ( Site 0585)

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine (

    Kyiv, Ukraine

  • Ondokuz Mayıs Universitesi ( Site 0564)

    Samsun, 55139, Turkey (Türkiye)

  • Országos Onkológiai Intézet-HEMATOLÓGIA ÉS LYMPHOMA OSZTÁLY KEMOTERÁPIA A ( Site 0405)

    Budapest, Pest County, 1122, Hungary

  • Ospedale San Raffaele-Unità Linfomi ( Site 0382)

    Milan, Lombardy, 20132, Italy

  • Pitie Salpetriere University Hospital-Clinical haematology ( Site 0304)

    Paris, 75013, France

  • Policlinico S. Orsola- Malpighi-Istituto di Ematologia "L. e A. Seragnoli" ( Site 0381)

    Bologna, 40138, Italy

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0031)

    Toronto, Ontario, m5g2m9, Canada

  • Pécsi Tudományegyetem Klinikai Központ-I.sz. Belgyógyászati Klinika Hematológia ( Site 0401)

    Pécs, Baranya, 7624, Hungary

  • Rambam Health Care Campus ( Site 0526)

    Haifa, 3109601, Israel

  • Rigshospitalet-Hematology - CTU ( Site 0361)

    Copenhagen, Capital Region, 2100, Denmark

  • Russian Scientific Research Institute of Hematology and Blood Transfusion-Hematology ( Site 0542)

    Saint Petersburg, Sankt-Peterburg, 191024, Russia

  • Rutgers Cancer Institute of New Jersey ( Site 0023)

    New Brunswick, New Jersey, 08901, United States

  • Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 0403)

    Budapest, 1088, Hungary

  • Sheba Medical Center-Hemato Oncology ( Site 0524)

    Ramat Gan, 5262100, Israel

  • Soroka Medical Center-Hematology Department ( Site 0523)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 0525)

    Tel Aviv, 64239, Israel

  • Universitaetsklinikum Essen ( Site 0327)

    Essen, North Rhine-Westphalia, 45122, Germany

  • Universitaetsklinikum Hamburg-Eppendorf-II. medical clinic ( Site 0332)

    Hamburg, 20246, Germany

  • Universitaetsklinikum Koeln-Klinik I für Innere Medizin ( Site 0321)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University of Chicago Medical Center ( Site 0005)

    Chicago, Illinois, 60637, United States

  • University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021

    Aurora, Colorado, 80045, United States

  • University of Texas MD Anderson Cancer Center ( Site 0014)

    Houston, Texas, 77030, United States

  • Universitätsklinikum Leipzig ( Site 0328)

    Leipzig, Saxony, 04103, Germany

  • Universitätsklinikum Marburg ( Site 0333)

    Marburg, Hesse, 35033, Germany

  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site

    Wrocaw, Lower Silesian Voivodeship, 50-556, Poland

  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0424)

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Vehbi Koc Vakfi - Amerikan Hastanesi ( Site 0562)

    Istanbul, 34365, Turkey (Türkiye)

  • centre hospitalier lyon sud-Service Hématologie ( Site 0300)

    Pierre-Bénite, Rhone, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.